

## EQA round: RF1/23 - Diagnostics of Rheumatoid Arthritis and ASLO

Deadline: 17.3.2023

Setup: groups - manufacturer of kit; Slovakia; minimal size of the groups n = 5

RoM = robust average	AV = assigned value	D <sub>max</sub> = acceptable difference
SD = standard deviation	CVPG = consensus of the participants' groups	LL = lower limit
CV = coefficient of variation	U <sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)	UL = upper limit
N <sub>tot</sub> = total number of the results		N <sub>eva</sub> = number of the results assessed
N <sub>out</sub> = number of the results removed before calculation		N <sub>suc</sub> = number of successful results
		S <sub>rel</sub> = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	Comparability					N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub> [%]
							AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL			
(237) <b>anti-streptolysin O (ASLO)</b>	[kU/L]				20							18	18	100
<b>Sample A2</b>		316	38	12	20							18	18	100
(58) Beckman Coulter (AU)		313	18	5,8	9	0	CVPG	319	8	20%	255	383	9	
(60) Roche		343	20	5,8	6	0	CVPG	345	5,8	20%	276	414	6	
Other					5	0							3	
							2x 1, 1x 162, 2x 178							
<b>Sample B2</b>		77,1	10	13	20							18	18	100
(58) Beckman Coulter (AU)		75,8	5,5	7,2	9	0	CVPG	79,3	3,6	20%	63,4	95,2	9	
(60) Roche		79,3	14	17	6	0	CVPG	82,4	2,6	20%	65,9	98,9	6	
Other					5	0							3	
							2x 1, 1x 162, 2x 178							